NAT2 Involed in the Susceptibility to Antituberculosis Drug-Induced Liver Injury
Article ID: 754
Abstract
Keywords
Full Text:
PDFReferences
[1] Dye C, Watt CJ, Bleed DM, et al.C. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally[J]. JAMA, 2005, 293(22):2790-2793.
[2] Agal S, Baijal R, Pramanik S, et al. Monitoring and management of antituberculosis drug induced hepatotoxicity[J]. J Gastroenterol Hepatol, 2005, 20(11):1745-1752.
[3] XUE Hong Yuan, HOU Yan Ning, LIU Hui Chen,et al. Study On the Mechanisms of Increased Hepatotoxicity of Rifampicin Plus Isoniazid in mice[J].Pharm J Chin PLA, 2002,18(6):330-333.
[4] Sang-Heon Kim , Sang-Hoon Kim , Ho Joo Yoon, et al. GSTT1 and GSTM1 null mutations and adverse reactions induced by antituberculosis drugs in Koreans[J]. Tuberculosis, 2010, 90 (1): 39-43.
[5] Bose PD, Sarma MP, Medhi S, et al. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis[J]. J Gastroenterol Hepatol, 2011,26(2):312-318.
[6] Saukkonen JJ, Cohn DL, Jasmer RM, et al. An offcial ATS statement: hepatotoxicity of antituberculosis therapy [J]. Am J Resp ir Crit.Care Med, 2006,174(8):935-952.
[7] Ng CS, Hasnat A, Al Maruf A, et al. N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group[J].Eur J Clin Pharmacol, 2014, 70(9):1079-
[8]
[9] Sharma SK, Balamurugan A, Saha PK,et al. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment[J]. Am. J. Respir. Crit. Care Med,2002, 166(7): 916-919.
[10] Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis[J]. Am. J. Respir. Crit. Care Med, 2003,
[11] (11):1472-1477.
[12] Mushiroda T, Yanai H, Yoshiyama T, et al. Development of a prediction system for antituberculosis drug-induced liver injury in Japanese patients [J].Hum Genome Var, 2016, 3:16014.
[13] Shi J, Xie M, Wang J, et al. Susceptibility of N acetyltransferase 2 slow acetylators to antituberculosis
[14] drug-induced liver injury: a meta-analysis[J].Pharmacogenomics, 2015 , 16(18):2083-97.
[15] Wilke RA, Lin DW, Roden DM, et al. Identifying genetic risk factors for serious adverse drug reactions:current progress and challenges [J].Nat Rev Drug Discov, 2007, 6(11):904-916.
[16] Stephens EA, Taylor JA, Kaplan N, et al. Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese [J]. Pharmacogenetics , 1994, 4(4):185-192.
[17] Adrian J, Fretland, Mattew, et al. Functional characterization of human N-acetyltransferase(NAT2) single nucleotide polymorphisms [J]. Pharmacogenetics,2001, 11:207-215.
[18] Bing Chen, Jin-Heng Li, Yi-Min Xu, et al. The influence of NAT2 genotypes on the plasma concentration of isoniazid and acetylisoniazid in Chinese pulmonary tuberculosis patients[J]. Clinica Chimica Acta,2006, 365:104-108.
[19] Yu Zang, Mark A. Doll, Shuang Zhao, et al. Functional Characterization of Single Nucleotide Polymorphisms and Haplotypes of Human N-Acetyltransferase 2[J]. Carcinogenesis, 2007, 28(8):1665-1671.
[20] Yi-Shin Huang, Herng-Der Chern, Wei-Juin Su.et al. Polymorphism of the N-Acetyltransferase 2 Gene as a Susceptibility Risk Factor for Antituberculosis Drug–Induced Hepatitis[J]. Hepatology, 2002,35(4):883-889.
[21] Hyun-Jung Cho, Won-Jung Koh, Yon-Ju Ryub, et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis[J]. Tuberculosis, 2007, 87(6): 551-556.
[22] Khalili H, Fouladdel S, Sistanizad M, et al. Association of N-acetyltransferase-2 genotypes and antituberculosis induced liver injury; frst case-controlled study from Iran[J]. Curr Drug Saf. 2011, 6(1):17-22.
[23] WANG Jin-he,LIU Jin-wei,WU Xue-qiong, et al. The study on the susceptible gene of isoniazid and rifampicin-induced hepatotoxicity of pulmonary tuberculosis patients[J]. Academic Journal of Pla Postgraduate Medical School, 2004,25(3):239-240.
[24] Sharma SK, Jha BK, Sharma A, et al. Genetic polymorphisms of N-acetyltransferase 2 & susceptibility to antituberculosis drug-induced hepatotoxicity[J]. Indian J Med Res, 2016, 144(6):924-928.
[25] Guaoua S, Ratbi I, El Bouazzi O, et al. NAT2 Genotypes in Moroccan Patients with Hepatotoxicity Due to Antituberculosis Drugs[J].Genet Test Mol Biomarkers. 2016, 20(11):680-684.
[26] Sang-Heon Kim, Sang-Hoon Kim,Joon-Woo Bahn,et al.Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis[J].Pharmacogenomics, 2009, 10(11):1767-1779.
[27] Possuelo LG, Castelan JA, de Brito TC, et al. Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil [J].Eur J Clin Pharmacol, 2008,64(7):673-681.
DOI: https://doi.org/10.30564/jams.v2i3.754
Refbacks
- There are currently no refbacks.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.